tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Angioedema D000799 6 associated lipids
Anus Diseases D001004 3 associated lipids
Apraxias D001072 1 associated lipids
Arm Injuries D001134 1 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Ascites D001201 25 associated lipids
Ataxia D001259 20 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Bacterial Infections D001424 21 associated lipids
Balanitis D001446 4 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Behcet Syndrome D001528 7 associated lipids
Biliary Fistula D001658 13 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Blepharitis D001762 4 associated lipids
Blindness D001766 6 associated lipids
Body Weight D001835 333 associated lipids
Bone Diseases D001847 4 associated lipids
Bradycardia D001919 13 associated lipids
Brain Diseases D001927 27 associated lipids
Brain Edema D001929 20 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Charpentier B Induction versus non-induction protocols in anti-calcineurin-based immunosuppression. 2001 Nov-Dec Transplant. Proc. pmid:11750425
López Lago AM et al. Evolution of hepatorenal syndrome after orthotopic liver transplantation: comparative analysis with patients who developed acute renal failure in the early postoperative period of liver transplantation. 2007 Transplant. Proc. pmid:17889176
van Duijnhoven E et al. The effect of breakfast on the oral bioavailability of tacrolimus in diabetic and nondiabetic patients before transplantation. 1998 Transplant. Proc. pmid:9636515
Crespo M et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. 2009 Jul-Aug Transplant. Proc. pmid:19715848
Riveiro-Barciela M et al. Hyperkalemic distal renal tubular acidosis caused by immunosuppressant treatment with tacrolimus in a liver transplant patient: case report. 2011 Transplant. Proc. pmid:22172892
Pascual J et al. One-center comparison between primary immunosuppression based on neoral cyclosporine and tacrolimus for renal transplantation. 2002 Transplant. Proc. pmid:11959200
Ericzon BG Early graft function in liver transplantation patients. 1994 Transplant. Proc. pmid:7527965
Gunji Y et al. Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK 506, rapamycin, or RS-61443. 1993 Transplant. Proc. pmid:7679841
Gregory CR et al. Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. 1993 Transplant. Proc. pmid:7679842
Jain AB et al. Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. 1991 Transplant. Proc. pmid:1721274
Lee KK et al. Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. 1990 Transplant. Proc. pmid:1689908
McMichael J et al. Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. 1991 Transplant. Proc. pmid:1721275
Namii Y et al. Tetrahydropyranyladriamycin with FK 506 combination therapy for hamster-to-rat-concordant xenotransplantation. 1996 Transplant. Proc. pmid:8623358
Valdivia LA et al. Prolonged survival of hearts obtained from chimeric donors in a mouse to rat xenotransplant model. 1996 Transplant. Proc. pmid:8623371
Melo MJ et al. Impact of conversion from Advagraf to twice-daily generic tacrolimus in kidney transplant recipients: a single-center study. 2015 Transplant. Proc. pmid:26036484
Bilbao I et al. Experience with neoral cyclosporine through the oral route in liver transplantation. 1998 Transplant. Proc. pmid:9636580
Braun F et al. An ex vivo model to study the intestinal biotransformation of immunosuppressive drugs. 2000 Transplant. Proc. pmid:11120037
Langrehr JM et al. Comparison of quadruple induction including ATG or IL-2R antibody with FK506-based therapy after liver transplantation. 1998 Transplant. Proc. pmid:9636583
Nakao A et al. Combined effect of donor-specific bone marrow transplantation via portal vein and FK506 on small bowel transplantation in the rat. 2000 Transplant. Proc. pmid:11120044
Viganó J et al. Incidence of graft rejection in small bowel transplanted pigs after immunosuppression withdrawal. 2006 Jul-Aug Transplant. Proc. pmid:16908291
Undre NA et al. Pharmacokinetics of tacrolimus: clinically relevant aspects. 1999 Transplant. Proc. pmid:10576037
Yilmaz A et al. Severe angioedema caused by banana allergy under tacrolimus immunosuppression. 2005 Transplant. Proc. pmid:16387091
Lai WJ et al. Is sirolimus a safe alternative to reduce or eliminate calcineurin inhibitors in chronic allograft nephropathy in kidney transplantation? 2004 Transplant. Proc. pmid:15518744
Colak H et al. Relationship of Interleukin-10 and Transforming Growth Factor-β Levels With Short-Term Graft Function After Kidney Transplantation. 2015 Transplant. Proc. pmid:25964218
Rosborough SL et al. Identification of FKBP-related proteins with antibodies of predetermined specificity and isolation by FK 506 affinity chromatography. 1991 Transplant. Proc. pmid:1721306
Metcalfe S et al. FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. 1990 Transplant. Proc. pmid:1697107
Morris RE et al. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. 1990 Transplant. Proc. pmid:1697111
Zhao DQ et al. Sirolimus-Based Immunosuppressive Regimens in Renal Transplantation: A Systemic Review. Transplant. Proc. pmid:26915834
Li D et al. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. 2006 Transplant. Proc. pmid:17112846
Azuma T et al. Study of graft-infiltrating cells in the rat small bowel allograft using low-dose FK 506. 1999 Transplant. Proc. pmid:10578293
Antoniou EA et al. Effect of donor-specific transfusion in combination with FK 506 in rat cardiac allotransplantation. 1999 Transplant. Proc. pmid:10578296
Andres A et al. Impact of a sirolimus/tacrolimus-based immunosuppressive regimen on kidney function after islet transplantation. 2005 Transplant. Proc. pmid:15848711
Petan JA et al. Physiochemical properties of generic formulations of tacrolimus in Mexico. 2008 Transplant. Proc. pmid:18589125
Ippoliti G et al. Serum cytokine levels after small bowel transplantation in pigs. 1994 Transplant. Proc. pmid:7518146
Abecassis MM et al. Patient outcomes and economics of once-daily tacrolimus in renal transplant patients: results of a modeling analysis. 2008 Transplant. Proc. pmid:18589126
Orita T et al. Effect of FK 506 in combination with prednisolone on the graft-vs-host reaction after small bowel transplantation in rats. 1994 Transplant. Proc. pmid:7518147
Timmermann W et al. A randomised trial comparing the efficacy and safety of tacrolimus with microemulsified cyclosporine after liver transplantation. 2002 Transplant. Proc. pmid:12176463
Ohtsuka S et al. The effect of short-term FK 506 therapy on pancreas transplantation using the cuff technique in rats. 1992 Transplant. Proc. pmid:1376532
Ko S et al. Significance of newly developed liposomal FK 506 in canine liver transplantation. 1995 Transplant. Proc. pmid:7533406
Hassoun Z et al. The choice of calcineurin inhibitor does not influence centrilobular necrosis after orthotopic liver transplantation. 2002 Transplant. Proc. pmid:12176464
McDiarmid SV et al. FK 506 rescue therapy in liver transplantation: outcome and complications. 1991 Transplant. Proc. pmid:1721339
Opelz G Evaluation of immunosuppressive induction regimens in renal transplantation. Collaborative Transplant Study. 1998 Transplant. Proc. pmid:9865286
Rintala JM et al. The effect of FK778 on acute rat renal allograft rejection and expression of platelet-derived growth factor and transforming growth factor-beta. 2006 Transplant. Proc. pmid:17098049
Zhou W et al. Calcineurin inhibitors block B-1 cell differentiation: the relevance to immunosuppressive treatment in ABO-incompatible transplantation. 2005 Transplant. Proc. pmid:15919474
Niel OR et al. Long-term glomerular filtration rate in liver allograft recipients according to the type of calcineurin inhibitors. 2009 Transplant. Proc. pmid:19857743
Spada M et al. Tacrolimus and mycophenolate mofetil in pig small bowel transplantation: different protocols and their outcome. 1997 Transplant. Proc. pmid:9142286
Charco R et al. Low incidence of hypercholesterolemia among liver transplant patients under tacrolimus monotherapy immunosuppression. 2002 Transplant. Proc. pmid:12176482
Cheng CY et al. Intervention of Online Percent Coefficient of Variation Reporting System Reduces the Variability of Tacrolimus Trough Concentration in Kidney Transplant Recipients. 2018 Transplant. Proc. pmid:30316366
Fries D et al. Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation. 1991 Transplant. Proc. pmid:1721370
Liu Y et al. Delayed Initiation of Tacrolimus Is Safe and Effective in Renal Transplant Recipients With Delayed and Slow Graft Function. 2018 Transplant. Proc. pmid:30316359
Jain AB et al. Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1703354
Wijnen RM et al. Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. 1991 Transplant. Proc. pmid:1721371
Venkataramanan R et al. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1703355
Goh BL et al. FK506 rescue therapy for acute renal allograft rejection. 1998 Transplant. Proc. pmid:9838574
Goh BL and Tan SY FK506 "rescue" therapy complicated by renal tubular acidosis in renal allograft recipients. 1998 Transplant. Proc. pmid:9838575
Melk A et al. P-glycoprotein expression in patients before and after kidney transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083115
Watanabe T et al. Effects of the endothelin-1 receptor antagonist TAK-044 on pulmonary injury in discordant xenotransplantation. 2000 Transplant. Proc. pmid:10936270
Tacrolimus in renal transplantation: a comparison of induction vs noninduction therapy (triple therapy): three-month results. 1999 Feb-Mar Transplant. Proc. pmid:10083131
Takayama K et al. Hepatocyte growth factor and vascular endothelial growth factor expression in pig-to-primate xenotransplanted hearts. 2000 Transplant. Proc. pmid:10936314
Veroux P et al. Tacrolimus-induced neurotoxicity in kidney transplant recipients. 2002 Transplant. Proc. pmid:12493415
Izbicki G et al. Improved survival after lung transplantation in patients treated with tacrolimus/mycophenolate mofetil as compared with cyclosporine/azathioprine. 2002 Transplant. Proc. pmid:12493439
Katoh H et al. Effectiveness of 15-deoxyspergualin on steroid-resistant acute rejection in living related liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123125
Meiser BM et al. Tacrolimus (FK506) proves superior to OKT3 for treating episodes of persistent rejection following intrathoracic transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123150
Takeuchi H et al. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level. 2008 Transplant. Proc. pmid:18790203
Scolari MP et al. Acute rejection after renal transplantation with tacrolimus-based therapy in conditions of normal clinical practice. 2002 Transplant. Proc. pmid:12176529
Shimizu T et al. Clinical and histological analysis of chronic tacrolimus nephrotoxicity in renal allografts. 2008 Transplant. Proc. pmid:18790237
Ushigome H et al. Immunosuppression in cadaveric renal transplant recipients from non-heart-beating donors in a single center. 2002 Transplant. Proc. pmid:12176533
Arita S et al. Effect of FK 506 in experimental pancreas transplantation. 1995 Transplant. Proc. pmid:7536980
Viebahn R et al. Hypoxic and reoxygenation injury in human and rat hepatocytes--influence of FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721401
Sato K et al. Effectiveness of triple drug immunosuppression for pancreaticoduodenal allotransplantation in dogs. 1992 Transplant. Proc. pmid:1379753
Masaki Y et al. Microchimerism and rat small bowel transplantation combined with donor-type bone marrow cells. 1996 Transplant. Proc. pmid:8769154
Murphy MP and Morris RE Brequinar sodium effectively and potently suppresses allograft rejection in a heterotopic mouse heart transplant model. 1993 Transplant. Proc. pmid:7685955
Kobayashi C et al. Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506. 1989 Transplant. Proc. pmid:2468254
Mohamed MA et al. The effect of cyclosporin A and tacrolimus on cultured human epithelial cells: the role of TGF-beta. 1999 Feb-Mar Transplant. Proc. pmid:10083523
Furtado A et al. Local immunosuppression in clinical small bowel transplantation (report of two cases). 2000 Transplant. Proc. pmid:10995910
Ayar Y et al. Risk Factors Affecting Graft and Patient Survivals After Transplantation From Deceased Donors in a Developing Country: A Single-Center Experience. 2017 Transplant. Proc. pmid:28219583
Sheng H et al. Ocular complications of heart transplantation in a Chinese population. 2008 Transplant. Proc. pmid:19100445
Chariat MN et al. Basiliximab in the therapy of acute rejection after organ transplantation. 2001 Transplant. Proc. pmid:11377567
Chan MC et al. Conversion of cyclosporine to tacrolimus for refractory or persistent myocardial rejection. 2002 Transplant. Proc. pmid:12176601
Yamanaka K et al. Induction Immunosuppressive Therapy With Everolimus and Low-Dose Tacrolimus Extended-Release Preserves Good Renal Function at 1 Year After Kidney Transplantation. 2016 Transplant. Proc. pmid:27234735
Akbas SH et al. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. 2006 Transplant. Proc. pmid:16797284
Franke GH et al. Switching from cyclosporine to tacrolimus leads to improved disease-specific quality of life in patients after kidney transplantation. 2006 Transplant. Proc. pmid:16797285
Kobayashi N et al. Effect of FK 506 on abdominal organ cluster transplantation in pigs. 1991 Transplant. Proc. pmid:1721434
Felipe CR et al. Choosing the right dose of new immunossuppressive drugs for new populations: importance of pharmacokinetic studies. 2001 Feb-Mar Transplant. Proc. pmid:11267207
Evans NJ et al. The expression of endothelin and inducible nitric oxide synthase in human renal allografts and their role in chronic renal allograft nephropathy. 2001 Feb-Mar Transplant. Proc. pmid:11267247
Collier DS et al. Kidney transplantation in the dog receiving FK-506. 1987 Transplant. Proc. pmid:2445077
Minematsu T et al. Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients. 2004 Transplant. Proc. pmid:15251372
Dikow R et al. Blood pressure profile and treatment quality in liver allograft recipients-benefit of tacrolimus versus cyclosporine. 2004 Transplant. Proc. pmid:15251373
Busuttil RW and Holt CD Tacrolimus is superior to cyclosporine in liver transplantation. 1998 Transplant. Proc. pmid:9723432
Gasser M et al. Effect of selective immunosuppression with FK 506, anti-IL-2R, and anti-ICAM-1 MAb in rat small bowel transplantation. 1998 Transplant. Proc. pmid:9745510
Jonas S et al. Five-year follow-up of tacrolimus as primary immunosuppressant after liver transplantation. 1998 Transplant. Proc. pmid:9723433
Dutta S et al. Liposomal tacrolimus and intestinal drug concentration. 1998 Transplant. Proc. pmid:9745533
Toyoki Y et al. Primary immunosuppression regimen of rapid steroid withdrawal after living related liver transplantation: a single-center experience. 2004 Transplant. Proc. pmid:15561218
Yoshimura R et al. Effect of immunosuppressive drugs (CsA, FK 506, rapamycin) on the kidney microsomal cytochrome P-450 system in the rat. 1994 Transplant. Proc. pmid:7524223
Burke GW et al. Ten-year survival after simultaneous pancreas/kidney transplantation with bladder drainage and tacrolimus-based immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267467
Kobashigawa JA Controversies in heart and lung transplantation immunosuppression: tacrolimus versus cyclosporine. 1998 Transplant. Proc. pmid:9636445
Rieber J et al. Effects of tacrolimus and cyclosporine on the coronary microcirculation after heart transplantation: a prospective study with serial intracoronary flow measurements. 1998 Transplant. Proc. pmid:9636446
Wong YT et al. Audit of diabetes in a renal transplant population. 2005 Transplant. Proc. pmid:16298573
Groth CG Immunosuppressive regimens of tomorrow. 1995 Transplant. Proc. pmid:8539797
Jiang H et al. Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703702